Shamburg News · 8-K filed Nov 2, 2026, 7:15 AM EST

Inovio Receives FDA Accelerated Approval for VOCERYQ to Reduce Surgery in Adults with RRP

INO · INOVIO PHARMACEUTICALS, INC.

  • Other event
  • Other
  • Materiality: high

On October 30, 2026, Inovio Pharmaceuticals announced that the FDA granted accelerated approval for VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), previously INO-3107, to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis. The approval is based on complete response, defined as no requirement for surgical intervention in the 12 months after treatment in the efficacy population, and continued approval may depend on a confirmatory study. The company expects to make VOCERYQ available to order and ship in approximately 60 days and anticipates full field deployment in the first quarter of 2027.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 7.01, 8.01, 9.01, accession 0001193125-26-442648.

Written from the filing by Shamburg Markets. Figures are as reported by the company.